pexidartinib-resistant FLT3 mutants don't bind pexidartinib

Stable Identifier
Reaction [transition]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

The following FLT3 mutants are resistant to inhibition by pexidartinib:
FLT3 D835F (Smith et al, 2012; 2013; 2015a, b)
FLT3 D835H (Smith et al, 2012; 2013; 2015a, b)
FLT3 D835V (Smith et al, 2012; 2013; 2015a, b)
FLT3 D835Y (Smith et al, 2012; 2013; 2015a, b)

Literature References
PubMed ID Title Journal Year
25847190 Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397

Smith, CC, Zhang, C, Lin, KC, Lasater, EA, Zhang, Y, Massi, E, Damon, LE, Pendleton, M, Bashir, A, Sebra, R, Perl, A, Kasarskis, A, Shellooe, R, Tsang, G, Carias, H, Powell, B, Burton, EA, Matusow, B, Zhang, J, Spevak, W, Ibrahim, PN, Le, MH, Hsu, HH, Habets, G, West, BL, Bollag, G, Shah, NP

26108694 FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

Smith, CC, Lin, K, Stecula, A, Sali, A, Shah, NP

Leukemia 2015
22504184 Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Smith, CC, Wang, Q, Chin, CS, Salerno, S, Damon, LE, Levis, MJ, Perl, AE, Travers, KJ, Wang, S, Hunt, JP, Zarrinkar, PP, Schadt, EE, Kasarskis, A, Kuriyan, J, Shah, NP

Nature 2012
23430109 Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Smith, CC, Lasater, EA, Zhu, X, Lin, KC, Stewart, WK, Damon, LE, Salerno, S, Shah, NP

Blood 2013
Participant Of
Normal reaction
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!